Karuna Therapeutics Inc. (KRTX)
$329.83
$0.00 (0.00%)As on 18-Mar-2024 09:30EDT
Market cap
$12,599 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
10
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-201 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-23
-
Debt to Equity
0
-
Book Value
$33.9
-
EPS
$-11.7
-
Face value
--
-
Shares outstanding
38,199,300
7 Years Aggregate
CFO
$-834.89 Mln
EBITDA
$-1,055.46 Mln
Net Profit
$-990.76 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
| 4.2 | 3.6 | 50.1 | 72.1 | 39.4 | -- | -- |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Midcap 400#
| 11.2 | -1.0 | -0.1 | 14.4 | 12.0 | 6.2 | 9.0 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
| 61.1 | 50.0 | 28.9 | 34.8 |
|
S&P Midcap 400
| 14.4 | -14.5 | 23.2 | 11.8 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Karuna Therapeutics (KRTX)
|
329.8 | 12,599.3 | 0.7 | -433.7 | -75,845.7 | -36.4 | -- | 10.0 |
| 23.0 | 492.4 | 37.3 | -30.9 | -102.2 | -1174.5 | -- | 108.4 | |
| 15.3 | 769.0 | 0.0 | -92.6 | -- | -42.8 | -- | 3.3 |
Shareholding Pattern
View DetailsAbout Karuna Therapeutics (KRTX)
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of... muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. Read more
-
Founder and President of Research & Development
Dr. Andrew Craig Miller Ph.D.
-
Founder and President of Research & Development
Dr. Andrew Craig Miller Ph.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Karuna Therapeutics (KRTX)
What is the current share price of Karuna Therapeutics Inc (KRTX) Today?
The share price of Karuna Therapeutics Inc (KRTX) is $329.83 (NASDAQ) as of 18-Mar-2024 09:30 EDT. Karuna Therapeutics Inc (KRTX) has given a return of 39.35% in the last 3 years.
What is the current PB & PE ratio of Karuna Therapeutics Inc (KRTX)?
Since, TTM earnings of Karuna Therapeutics Inc (KRTX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-27.00 |
9.34 |
2022 |
-22.75 |
5.58 |
2021 |
-26.42 |
7.57 |
2020 |
-38.53 |
7.79 |
2019 |
-20.16 |
2.32 |
What is the 52 Week High and Low of Karuna Therapeutics Inc (KRTX)?
The 52-week high and low of Karuna Therapeutics Inc (KRTX) are Rs -- and Rs -- as of 02-Sep-2026.
What is the market cap of Karuna Therapeutics Inc (KRTX)?
Karuna Therapeutics Inc (KRTX) has a market capitalisation of $ 12,599 Mln as on 18-Mar-2024. As per SEBI classification, it is a Mid Cap company.
Should I invest in Karuna Therapeutics Inc (KRTX)?
Before investing in Karuna Therapeutics Inc (KRTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.